Skip to main content
SpringerLink
Log in

Proposed pharmacovigilance definitions of ‘signal of suspected causality’ should be helpful in assessing benefits and harms

  • Practical Issues and Updates
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1

References

  1. Hauben M, Aronson, JK. Defining ’signal’ and its subtypes in pharmacovigilance based on a systematic review of previous definitions. Drug Saf 2009; 32(2): 99–110

    Article  PubMed  Google Scholar 

  2. Cobert BL, Biron P. Pharmacovigilance from A to Z: adverse drug event surveillance. Oxford: Blackwell Science, 2002: 191–2

    Google Scholar 

  3. Hauben M, Madigan D, Gerrits C, et al. The role of data mining in pharmacovigilance. Expert Opin Drug Saf 2005; 4(5): 929–48

    Article  PubMed  CAS  Google Scholar 

  4. Cohen A. Should we tolerate tolerability as an objective in early drug development? Br J Clin Pharmacol 2007; 64(3): 249–52

    Article  PubMed  CAS  Google Scholar 

  5. World Health Organization. Safety of medicines: a guide to detecting and reporting adverse drug reactions [online]. Available from URL: http://www.who.int [Accessed 2009 Sep 16]

  6. Meyboom RH, Egberts AC, Edwards IR, et al. Principles of signal detection in pharmacovigilance. Drug Saf 1997; 16(6): 355–65

    Article  PubMed  CAS  Google Scholar 

  7. CIOMS Working Group IV. Benefit-risk balance for marketed drugs: evaluating safety signals. Geneva: WHO, 1998

    Google Scholar 

  8. CIOMS Working Group VI. Management of safety information from clinical trials. Geneva: WHO, 2005

    Google Scholar 

  9. US Food and Drug Administration. Guidance for industry: good pharmacovigilance practices and pharmacoepidemiologic assessment. 2005 [online]. Available from URL: http://www.fda.gov [Accessed 2009 Sep 16]

  10. Metters J. Report of an independent review of access to the yellow card scheme. London: The Stationery Office, 2004

    Google Scholar 

  11. Coulter DM. The New Zealand Intensive Medicines Monitoring Programme in pro-active safety surveillance. Pharmacoepidemiol Drug Saf 2000; 9(4): 273–80

    Article  PubMed  CAS  Google Scholar 

  12. Aronson JK, Loke Y, Derry S. Adverse drug reactions: keeping up to date. Fundam Clin Pharmacol 2002; 16(1): 49–56

    Article  PubMed  CAS  Google Scholar 

  13. Aronson JK, Hauben M. Anecdotes that provide definitive evidence. BMJ 2006; 333(7581): 1267–9

    Article  PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Proposed pharmacovigilance definitions of ‘signal of suspected causality’ should be helpful in assessing benefits and harms. Drugs Ther. Perspect 25, 24–26 (2009). https://doi.org/10.2165/0042310-200925110-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/0042310-200925110-00007

Search

Navigation